Table 5.
Contributions from studies with enrichment design to mixed and indirect estimates
| Depressive episode relapse | Mania episode relapse | |||||
|---|---|---|---|---|---|---|
| In favour of the drug to the right (%) | In disfavour of the drug to the right (%) | Enrichment of unknown direction (%) | In favour of the drug to the right (%) | In disfavour of the rug to the right (%) | Enrichment of unknown direction (%) |
|
| PLB vs LIT | 12.12 | 10.49 | 0.05 | 5.73 | 6.83 | 0.24 |
| PLB vs VPA | 5.51 | 0.00 | 4.82 | 3.34 | 0.00 | 4.18 |
| PLB vs LTG | 48.26 | 0.00 | 1.94 | 21.75 | 0.00 | 1.51 |
| PLB vs IMP | 5.80 | 5.20 | 7.43 | 2.97 | 4.76 | 6.03 |
| PLB vs FLX | 68.79 | 0.00 | 3.02 | – | – | – |
| PLB vs LIT + IMP | 17.76 | 0.00 | 5.03 | 13.26 | 0.00 | 3.53 |
| PLB vs ARP | 0.00 | 0.00 | 0.00 | 99.90 | 0.00 | 0.00 |
| PLB vs OLZ | 2.59 | 0.00 | 2.25 | 45.83 | 20.40 | 0.22 |
| PLB vs QTP | 40.87 | 0.00 | 2.40 | 33.53 | 0.00 | 1.61 |
| PLB vs RisLAI | 0.69 | 0.00 | 0.58 | 72.94 | 0.00 | 0.03 |
| PLB vs PAL | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 |
When patients were recruited in manic (or depressive) episodes and stabilised with drug A and then after stabilisation randomised to drug A vs drug B, then such patients were considered to have been enriched against manic (or depressive) relapses but not for depressive (or manic) relapses. Contributions of the effects from studies with enrichment design to mixed or indirect comparisons were calculated as the sum of the proportion of such patients in each direct comparison, weighted by the contribution matrix
ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate